Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$13.95
-0.04-0.29%
At close: -
$13.95
0.000.00%
After Hours: 4:17 PM EDT
Comments
Loading...
Cross Country Healthcare Analyst Ratings and Price Targets | NASDAQ:CCRN | Benzinga
Cross Country Healthcare Inc has a consensus price target of $22.97 based on the ratings of 11 analysts. The high is $32 issued by Credit Suisse on February 23, 2023. The low is $16.5 issued by UBS on May 13, 2025. The 3 most-recent analyst ratings were released by UBS, Barrington Research, and Truist Securities on May 13, 2025, March 14, 2025, and December 5, 2024, respectively. With an average price target of $17.91 between UBS, Barrington Research, and Truist Securities, there's an implied 28.36% upside for Cross Country Healthcare Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
UBS
Barrington Research
Truist Securities
Benchmark
Jefferies
1calculated from analyst ratings
Analyst Ratings for Cross Country Healthcare
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/13/2025 | Buy Now | 18.28% | UBS | A.J. Rice69% | $18.61 → $16.5 | Maintains | Neutral | Get Alert |
| 03/14/2025 | Buy Now | 33.41% | Barrington Research | Kevin Steinke63% | $18.61 → $18.61 | Maintains | Market Perform | Get Alert |
| 02/06/2025 | Buy Now | — | JMP Securities | Constantine Davides41% | — | Reiterates | Market Perform → Market Perform | Get Alert |
| 12/10/2024 | Buy Now | — | Barrington Research | Kevin Steinke63% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 12/05/2024 | Buy Now | 33.41% | Truist Securities | Tobey Sommer72% | $15 → $18.61 | Maintains | Hold | Get Alert |
| 11/07/2024 | Buy Now | 29.03% | Benchmark | Bill Sutherland66% | $19 → $18 | Maintains | Buy | Get Alert |
| 10/21/2024 | Buy Now | 7.53% | Truist Securities | Tobey Sommer72% | $17 → $15 | Maintains | Hold | Get Alert |
| 08/08/2024 | Buy Now | 36.2% | Barrington Research | Kevin Steinke63% | $21 → $19 | Maintains | Outperform | Get Alert |
| 08/01/2024 | Buy Now | 21.86% | Truist Securities | Tobey Sommer72% | $16 → $17 | Maintains | Hold | Get Alert |
| 05/06/2024 | Buy Now | 50.54% | Barrington Research | Kevin Steinke63% | $24 → $21 | Maintains | Outperform | Get Alert |
| 05/02/2024 | Buy Now | 36.2% | Benchmark | Bill Sutherland66% | $21 → $19 | Maintains | Buy | Get Alert |
| 02/27/2024 | Buy Now | 72.04% | Barrington Research | Kevin Steinke63% | $26 → $24 | Maintains | Outperform | Get Alert |
| 02/22/2024 | Buy Now | 14.7% | Truist Securities | Tobey Sommer72% | $22 → $16 | Maintains | Hold | Get Alert |
| 02/22/2024 | Buy Now | 50.54% | Benchmark | Bill Sutherland66% | $24 → $21 | Maintains | Buy | Get Alert |
| 12/06/2023 | Buy Now | — | JMP Securities | Constantine Davides41% | — | Initiates | → Market Perform | Get Alert |
| 11/30/2023 | Buy Now | 57.71% | UBS | A.J. Rice69% | → $22 | Initiates | → Neutral | Get Alert |
| 11/29/2023 | Buy Now | 86.38% | Barrington Research | Kevin Steinke63% | $29 → $26 | Maintains | Outperform | Get Alert |
| 11/03/2023 | Buy Now | 57.71% | Truist Securities | Tobey Sommer72% | $25 → $22 | Maintains | Hold | Get Alert |
| 11/03/2023 | Buy Now | 50.54% | Jefferies | Brian Tanquilut46% | $32 → $21 | Downgrade | Buy → Hold | Get Alert |
| 10/05/2023 | Buy Now | 129.39% | Jefferies | Brian Tanquilut46% | $40 → $32 | Maintains | Buy | Get Alert |
| 08/14/2023 | Buy Now | 107.89% | Barrington Research | Kevin Steinke63% | $35 → $29 | Maintains | Outperform | Get Alert |
| 08/08/2023 | Buy Now | 86.38% | Credit Suisse | Jonathan Yong65% | $27 → $26 | Maintains | Neutral | Get Alert |
| 06/26/2023 | Buy Now | — | William Blair | Trevor Romeo51% | — | Initiates | → Outperform | Get Alert |
| 06/01/2023 | Buy Now | 150.9% | Barrington Research | Kevin Steinke63% | $42 → $35 | Maintains | Outperform | Get Alert |
| 05/05/2023 | Buy Now | 93.55% | Credit Suisse | Jonathan Yong65% | $32 → $27 | Maintains | Neutral | Get Alert |
| 05/02/2023 | Buy Now | 79.21% | Truist Securities | Tobey Sommer72% | $38 → $25 | Maintains | Hold | Get Alert |
| 03/10/2023 | Buy Now | 115.05% | Loop Capital | Joseph France64% | → $30 | Initiates | → Buy | Get Alert |
| 02/23/2023 | Buy Now | 186.74% | Benchmark | Bill Sutherland66% | $45 → $40 | Maintains | Buy | Get Alert |
| 02/23/2023 | Buy Now | 129.39% | Credit Suisse | Jonathan Yon51% | $31 → $32 | Maintains | Neutral | Get Alert |
| 11/07/2022 | Buy Now | 222.58% | Barrington Research | Kevin Steinke63% | $41 → $45 | Maintains | Outperform | Get Alert |
| 10/05/2022 | Buy Now | 158.06% | Truist Securities | Tobey Sommer72% | → $36 | Downgrade | Buy → Hold | Get Alert |
| 09/15/2022 | Buy Now | 201.08% | Benchmark | Bill Sutherland66% | $37 → $42 | Maintains | Buy | Get Alert |
| 06/13/2022 | Buy Now | 165.23% | Benchmark | Bill Sutherland66% | $42 → $37 | Maintains | Buy | Get Alert |
| 06/09/2022 | Buy Now | 86.38% | Credit Suisse | Nick Giovacchini49% | $28 → $26 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Cross Country Healthcare (CCRN) stock?
The latest price target for Cross Country Healthcare (NASDAQ:CCRN) was reported by UBS on May 13, 2025. The analyst firm set a price target for $16.50 expecting CCRN to rise to within 12 months (a possible 18.28% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cross Country Healthcare (CCRN)?
The latest analyst rating for Cross Country Healthcare (NASDAQ:CCRN) was provided by UBS, and Cross Country Healthcare maintained their neutral rating.
When was the last upgrade for Cross Country Healthcare (CCRN)?
There is no last upgrade for Cross Country Healthcare
When was the last downgrade for Cross Country Healthcare (CCRN)?
The last downgrade for Cross Country Healthcare Inc happened on December 10, 2024 when Barrington Research changed their price target from N/A to N/A for Cross Country Healthcare Inc.
When is the next analyst rating going to be posted or updated for Cross Country Healthcare (CCRN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cross Country Healthcare, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cross Country Healthcare was filed on May 13, 2025 so you should expect the next rating to be made available sometime around May 13, 2026.
Is the Analyst Rating Cross Country Healthcare (CCRN) correct?
While ratings are subjective and will change, the latest Cross Country Healthcare (CCRN) rating was a maintained with a price target of $18.61 to $16.50. The current price Cross Country Healthcare (CCRN) is trading at is $13.95, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
